— Company will explore strategic alternatives for its immuno-oncology programs — Company will align its resources to focus on HEPLISAV-B commercialization — Eddie Gray, CEO, to retire
BERKELEY, Calif., May 23, 2019 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (NASDAQ: DVAX), today announced a strategic restructuring to prioritize its vaccine business by focusing on the companys first commercial product HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]. As part of the restructuring, the company will explore strategic alternatives for its immuno-oncology portfolio and will reduce the companys workforce and operations to focus resources on HEPLISAV-B commercialization. While the companys near-term focus will be on HEPLISA…
Read the full article at: https://www.apnews.com/Globe Newswire/c041b8f72ba80eca6bf325168e8bab6c